effects [qlco]
Hormone replacement therapy [topp]
Insulin Resistance [patf]
Platelet Function Tests [lbpr]
objectives [inpr]
Study [mnob]
Evaluate [ftcn]
Measures [qnco]
Insulin Resistance [patf]
Platelet Function [lbpr]
postmenopausal [tmco]
Women [popg]
Oral [spco]
Transdermal [ftcn]
Hormone replacement therapy [topp]
Subject [grup]
Methods [inpr]
Women [popg]
divided [ftcn]
Group [idcn]
Study [mnob]
Group 1 [inpr]
postmenopausal [tmco]
Women [popg]
Received [qlco]
Transdermal [ftcn]
Estradiol [horm, phsu, strd]
9-MG [nnon]
Group 2 [inpr]
Women [popg]
Intact [qlco]
Uterus [bpoc]
treated [topp]
Estrogen [horm, phsu, strd]
Progestin [horm, phsu, strd]
Combination [qlco]
Hormone replacement therapy [topp]
Group 3 [inpr]
postmenopausal [tmco]
Women [popg]
treated [topp]
Selective Estrogen Receptor Modulator [horm, phsu]
tibolone [phsu, strd]
Group 4 [inpr]
Women [popg]
Take [hlca]
Drugs [phsu]
Hormone replacement therapy [topp]
Chosen [acty]
Control Group [grup]
Group 4 [inpr]
Group 2 [inpr]
Homeostasis model assessment [lbpr]
Insulin Resistance [patf]
Fasting [fndg]
insulin levels [lbpr]
>90 [qnco]
mU/mL [qnco]
Administration [ocac]
Hormone replacement therapy [topp]
Levels [qlco]
Reduced [qlco]
P NOS [aapp, imft]
mU/mL [qnco]
P NOS [aapp, imft]
Drug Therapy [topp]
Levels [qlco]
High sensitivity [lbpr]
Copyright [inpr]
Reactive [qlco]
Protein [aapp, bacs]
Decreased [qnco]
Hormone replacement therapy [topp]
Group 2 [inpr]
P NOS [aapp, imft]
Biochemical [ftcn]
Haematology NOS [bmod]
Parameters [fndg]
Observed [ftcn]
Group [idcn]
Platelet Function Tests [lbpr]
Hormone replacement therapy [topp]
Group [idcn]
Conclusions [idcn]
Estrogen Progestin Combination Therapy [topp]
hormone replacement [topp]
Decreased [qnco]
Measures [qnco]
Insulin Resistance [patf]
High sensitivity [lbpr]
C-reactive protein level [lbpr]
Platelet Function Tests [lbpr]
postmenopausal [tmco]
Women [popg]
Copyright [inpr]
basel [hcro]
